Vectibix (panitumumab) / Amgen, Takeda, Dr. Reddy’s - LARVOL DELTA

Drug-Induced Paronychia: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (AAD 2026) - "The most frequently reported drugs included panitumumab (14.2%), afatinib (8.8%), lapatinib (8.8%), fluorouracil (8.5%), oxaliplatin (7.4%), cetuximab (6.5%), and capecitabine (6.2%). This pharmacovigilance analysis identified multiple drugs associated with paronychia, emphasizing the importance of clinical awareness and further research into underlying mechanisms and risk factors."

Adverse events

Real-World Comparison of Later-Line Therapies in Metastatic Colorectal Cancer (HOPA 2026) - "Once a patient has progressed through all conventional treatment regimens including a fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab, and cetuximab (or panitumumab), three treatment regimens have become available as last-line therapy options. The primary objective is to assess differences in overall survival (OS) between regorafenib or fruquintinib when administered after FTD-TPI based therapy in heavily pretreated patients with metastatic colorectal cancer. Results; In Process"

Clinical • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

Safety and Efficacy of Panitumumab in Combination with Capecitabine versus Fluorouracil in Primarily Left-sided RAS Wild-Type Metastatic Colorectal Cancer: A Retrospective Review (HOPA 2026) - "Patients with RAS wild-type and left-sided tumors demonstrate improved response rates and survival outcomes when treated with epidermal growth factor receptor (EGFR) targeted therapies, such as panitumumab or cetuximab, with chemotherapy. First-line standard of care for this patient population involves combination chemotherapy with FOLFOX or FOLFIRI plus an EGFR inhibitor... Capecitabine/panitumumab may be a feasible oral maintenance alternative to fluorouracil/panitumumab with similar safety and survival outcomes."

Combination therapy • Metastases • Retrospective data • Review • Colorectal Cancer • Oncology • Solid Tumor • BRAF • KRAS • RAS

Preclinical combination approaches with the pan-KRAS inhibitor AMG 410 in KRAS-mutant cancers (AACR 2026) - "Guided by reverse translation findings from the G12C-selective inhibitor sotorasib, we evaluated AMG 410 combination approaches in preclinical models to proactively mitigate potential primary and acquired resistance mechanisms...Consistent with the in vitro synergy observed with pan-HER inhibition, the combination of AMG 410 with panitumumab resulted in tumor regression in a CRC PDX model...Finally, co-treatment with a TEAD inhibitor enhanced durability of response to AMG 410 in vivo. Taken together, these findings support the clinical investigation of AMG 410 combination strategies to extend the therapeutic benefit of KRAS inhibition across diverse KRAS-mutant cancers."

IO biomarker • Preclinical • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS • YAP1

TRO-02, a conditionally activated EGFR-targeting ADC incorporating TROCADTM and TROSIGTM platforms, shows enhanced tumor selectivity and potent efficacy (AACR 2026) - "TRO-02 is a DAR8-type ADC generated by conjugating a potent topoisomerase I inhibitor to panitumumab via a cleavable, stable, and hydrophilic TROSIGTM linker. Furthermore, pharmacokinetic analysis in rats demonstrated favorable PK properties (t1/2 = 4.47 days, AUC = 163.52 day·μg/mL, CL = 25.05 mL/day/kg, Vd = 0.08 L/kg at 4 mg/kg), indicating high in vivo stability and low clearance. Collectively, these findings demonstrate that TRO-02 is a conditionally activated EGFR-targeting ADC with improved therapeutic index, achieving potent antitumor efficacy while minimizing on-target/off-tumor toxicity."

ADC • Clinical • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ANXA1

Decoding ADC payload dynamics with a spatial transcriptomics-integrated tumor microenvironment PK model (AACR 2026) - "To validate these findings, we used a FaDu xenograft mouse model that received either fluorescently labeled cetuximab or panitumumab. We established a spatially-resolved TME-PK framework, which was validated preclinically using experimental xenograft data. Its application to STAD patient data confirmed known pharmacological phenomena, such as the binding-site barrier effect. This demonstrates the TME-PK model as a crucial tool for optimizing ADC payload delivery, showing that the optimal kinetic properties of antibody must be balanced against the spatial patterns of target expression and relationship with tumor microenvironment to ensure both binding and tissue penetration."

ADC • Biomarker • Tumor microenvironment • Gastric Adenocarcinoma • Oncology • CEACAM5 • NECTIN4

Evaluation of the circulating angiome in cancer: Translational assessment of a 44-plex angiogenesis biomarker panel (AACR 2026) - P1 | "Pharmacodynamic biomarker modulation was explored using retrospective plasma samples from two NCI studies —Cabozantinib + Panitumumab (NCT02008383) and Bevacizumab (NCT00416637)...This 44-plex panel demonstrates robust analytical performance, sensitivity, and reproducibility on the MSD® U-PLEX platform. The assay supports harmonized angiogenesis profiling, enabling standardized angiogenesis biomarker assessment in oncology research."

Biomarker • Oncology • IL6

Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib. (PubMed, J Clin Med) - "Trastuzumab-based combinations and HER2-selective tyrosine kinase inhibitors such as tucatinib have demonstrated durable responses and favorable safety profiles in heavily pretreated patients. This review summarizes current evidence from pivotal phase II and III clinical trials, translational studies, and real-world data evaluating EGFR-, BRAF-, and HER2-directed therapies in colorectal cancer. Particular emphasis is placed on biomarker-guided patient selection, mechanisms of resistance, and emerging combination strategies that continue to refine precision oncology approaches in mCRC."

Clinical • Journal • Review • Colorectal Cancer • Oncology • Solid Tumor • BRAF • HER-2

Immune and pharmacodynamic effects of sotorasib plus panitumumab in KRAS G12C-mutant colorectal cancer: Paired biopsy results from CodeBreaK 101 (AACR 2026) - P1 | "Paired biopsy analysis revealed potent MAPK inhibition and immune remodeling, providing mechanistic insight into the role of the immune TME in early response to sotorasib plus panitumumab and underscoring opportunities for rational combination strategies in mCRC."

Biopsy • PK/PD data • Colorectal Cancer • Oncology • Solid Tumor • CD8 • CXCL10 • CXCL9 • CXCR6 • DUSP6 • EPHA4 • ETV4 • HER-2 • HLA-DPA1 • IFNG • KRAS

Evolution of TOP1 variants under selective pressure from topoisomerase-based therapeutics (AACR 2026) - "Background: Antibody-drug conjugates (ADCs) that incorporate topoisomerase I inhibitor payloads, including sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), have demonstrated activity across multiple solid tumors...Patients exposed to topoisomerase inhibitor-based ADCs (SG, T-DXd, or datopotamab deruxtecan [Dato-DXd]) or irinotecan/topotecan-containing chemotherapy were identified (n = 1,807)... TOP1 alterations can appear after exposure to topoisomerase-payload ADCs or irinotecan-containing regimens, suggesting a potential resistance mechanism in a subset of patients. The functional impact of these variants and their relevance to therapeutic response remain undefined, warranting further mechanistic and clinical investigation."

Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • TOP1

ACR335, a novel cMET/EGFR bispecific dual-payload antibody-drug conjugate, demonstrates potent and broad antitumor activity in preclinical models of solid tumors (AACR 2026) - "Furthermore, ACR335 is engineered as a dual-payload ADC, combining a Topoisomerase I (Top1) inhibitor and a non-Top/non-Tubulin inhibitor, a strategy designed to synergistically maximize tumor cell killing. The BsAb IBR335 combines a fully human anti-cMET antibody (isolated from a naïve phage library) with an engineered version of panitumumab (anti-EGFR). ACR335 is a first-in-class cMET/EGFR bispecific dual-payload ADC with a unique pharmacological profile. The compelling preclinical data underscore its potential as a targeted therapy with an optimized safety profile. Phase I clinical trials are expected to commence in Q2 2026."

ADC • Bispecific • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TOP1

Differential in vitro activity of amivantamab, cetuximab, and panitumumab against EGFR ECD resistance mutations (AACR 2026) - P1/2 | "This participant achieved a partial response, providing preliminary clinical evidence that amivantamab is active against a mutation demonstrated to confer resistance to cetuximab. In conclusion, amivantamab may be more active against a wider range of EGFR ECD resistance mutations compared with cetuximab and panitumumab."

Preclinical • Colorectal Cancer • Oncology • Solid Tumor • BRAF • EGFR

Real-world overall survival with trastuzumab deruxtecan versus standard chemotherapy in HER2-amplified MSS metastatic colorectal cancer (AACR 2026) - "This study evaluated real-world overall survival (OS) with T-DXd versus standard chemotherapy in patients with MSS, HER2-amplified mCRC to assess effectiveness outside trial settings. De-identified TriNetX data (2010-2025) were used to identify adults (>18 years) with HER2-amplified mCRC treated with either second-line chemotherapy (FOLFOX, FOLFIRI, or CAPOX ± bevacizumab) or T-DXd as second-line of treatment. Because anti-EGFR therapy is ineffective in HER2-amplified disease, cetuximab- or panitumumab-treated patients were excluded... Although DESTINY-CRC01 evaluated T-DXd in the third-line or later setting, where patients had received a median of four prior therapies, this real-world analysis demonstrates that T-DXd is associated with improved long-term survival even when used in the second line setting, with fewer treatment-related adverse events. In patients with HER2-amplified mCRC, T-DXd showed a meaningful 5-year overall survival advantage compared with..."

Clinical • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor • HER-2

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation (clinicaltrials.gov) - P2 | N=14 | Recruiting | Sponsor: Amgen

Trial initiation date • Oncology • Solid Tumor

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Eben Rosenthal

New P1 trial • Brain Cancer • Glioblastoma • Meningioma • Oncology • Pituitary Gland Carcinoma • Solid Tumor

A RARE CASE OF URINARY PROTEIN LEAKAGE CAUSED BY RECTAL CANCER WITH BLADDER INVASION (ISN-WCN 2026) - "We present a rare case of rectal cancer with bladder invasion causing urinary protein leakage and hypoalbuminemia, which provides important diagnostic insights for the nephrotic syndrome.Methods A 53-year-old woman with rectal cancer invading the bladder, right ovary, and right ureter, complicated by right hydronephrosis, underwent colostomy and chemotherapy with FOLFOX plus panitumumab...Furthermore, a stepwise diagnostic process—beginning with renal biopsy, followed by urine route comparison, and culminating in scintigraphy—was essential to establishing the final diagnosis. By carefully integrating renal and extrarenal perspectives, this case broadened our differential diagnosis in nephrology and emphasized the need for vigilance in complex clinical scenarios, especially those involving oncologic backgrounds."

Clinical • Bladder Cancer • Colon Cancer • Colorectal Cancer • Glomerulonephritis • Nephrology • Oncology • Rectal Cancer • Renal Disease • Solid Tumor

A predictive model for treatment efficacy in RAS wild-type advanced colorectal cancer: development and external validation for EGFR inhibitor plus anti-angiogenic therapy based on a retrospective cohort. (PubMed, Sci Rep) - "This retrospective multi-center study included 600 RAS wild-type advanced CRC patients (development cohort: 420 patients from two centers; external validation cohort: 180 patients from an independent center) treated with EGFR inhibitors (cetuximab/panitumumab) plus anti-angiogenic agents (bevacizumab/fruquintinib/regorafenib) between 2018 and 2021. As a supplementary tool to current clinical guidelines, the model can partially address the problem of clinical response heterogeneity in combination therapy and provide simple decision support for clinicians in primary and secondary hospitals with limited detection conditions. However, the model has certain limitations in long-term prognostic prediction and needs to be further optimized and validated in larger, multi-center prospective cohorts before it can be translated into clinical practice of precision oncology."

Journal • Retrospective data • Tumor mutational burden • Colorectal Cancer • Oncology • Solid Tumor • CEACAM5 • TMB

Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b). (ASCO 2025) - P1, P3 | "Discontinuation of sotorasib, panitumumab, or FOLFIRI (5-FU, irinotecan, or leucovorin/levoleucovorin) due to AEs was observed in 1 (2.5%), 1 (2.5%), and 16 (40.0%) patients, respectively... Sotorasib plus panitumumab and FOLFIRI showed promising long-term safety and efficacy in pretreated KRAS G12C-mutated mCRC. AEs were consistent with the safety profile of the drugs administered. The ongoing phase 3 study, CodeBreaK 301 (NCT06252649), aims to evaluate this combination against standard of care in first-line patients with KRAS G12C-mutated mCRC."

Clinical • Metastases • P1 data • Colorectal Cancer • Dental Disorders • Dermatitis • Dermatology • Immunology • Oncology • Solid Tumor • Stomatitis • KRAS

Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research. (PubMed, Clin Transl Med) - "Tumour-targeted fluorescence-guided surgery (Ttfgs) enhances intraoperative precision in gastrointestinal cancer treatment. Translation of (Ttfgs) into clinical practice is limited by heterogeneity, regulatory hurdles, biomarker variability and absence of phase III trials. Innovations such as multimodal tracers and theranostic agents may further enhance the precision and therapeutic potential of Ttfgs."

Journal • Preclinical • Review • Gastrointestinal Cancer • Oncology • Solid Tumor • CEACAM5 • EGFR • EPCAM • FOLR1 • HER-2

Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial. (PubMed, Biomed Pharmacother) - "This exploratory analysis suggests that BW and BC may influence panitumumab PK, with patients who had lower BW, FM and FFM might have reduced exposure and clearance. Interpretation should be cautious due to the small sample size, confounding effect between BC and BW and potential disease-related effects. Larger studies with longitudinal BC and PK assessments are needed to clarify these relationships and guide dosing strategies."

Journal • P1 data • PK/PD data • Anal Carcinoma • Cachexia • Oncology • Squamous Cell Carcinoma

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. (PubMed, J Clin Oncol) - P2 | "Intermittent FOLFIRI plus PAN after the induction phase was feasible, and the primary end point was met with reduced toxicity while allowing patients more time off treatment."

Journal • Metastases • Colorectal Cancer • Oncology • Solid Tumor • BRAF • RAS

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. (PubMed, J Clin Oncol) - "In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC."

Journal • P3 data • Colorectal Cancer • Oncology • Solid Tumor • KRAS

FOxTROT: Predictive effects of ERBB2 and ERBB3 on neoadjuvant panitumumab benefit in RAS/BRAF wild-type (-wt) locally advanced colon cancer (LACC). (ASCO-GI 2026) - P2/3 | "High ERBB3 expression predicted benefit from neoadjuvant FOLFOX+pan. ERBB3 augmented the known predictive effect of the EGFR ligands, AREG/EREG. Validation in a biomarker-enriched trial is warranted."

Clinical • Metastases • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • AREG • BRAF • EGFR • ERBB3 • EREG • HER-2 • KRAS • RAS

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study. (PubMed, J Clin Oncol) - "Eligible patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovorin, oxaliplatin (mFOLFOX)/panitumumab (control group, n = 217) versus modified fluorouracil, leucovorin, oxaliplatin, irinotecan (mFOLFOXIRI)/panitumumab (experimental group, n = 218). Similar proportions of patients in both groups received subsequent lines of therapy (control/experimental: second line 73%/71%, third line 51%/49%, fourth line 31%/32%), as well as nonpalliative locoregional treatments (control/experimental: 16%/16%). Upfront mFOLFOXIRI/panitumumab significantly improves OS compared with mFOLFOX/panitumumab in patients with RAS/BRAF wild-type mCRC."

Journal • P3 data • Colorectal Cancer • Oncology • Solid Tumor • BRAF • RAS

#ComboMATCH Treatment Trial E5, led by @kspencer725 of @Perlmutter_CC and @DocDustyD of @UWCarbone , is a randomized phase 2 study of #sotorasib with or without #panitumumab in advanced #SolidTumors. Learn more here: https://bit.ly/combomatch-e5 #PrecisionMedicine

Clinical